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Patients requiring chronic transfusion support are at risk of 
alloimmunization after red blood cell (RBC) transfusion because 
of a disparity between donor and recipient antigen profiles. This 
research explored the probability of obtaining an exact extended 
phenotype match between blood donors randomly selected from 
our institution and patients randomly selected from particular 
ethnic groups. Blood samples from 1,000 blood donors tested by 
molecular method were evaluated for the predicted phenotype 
distribution of Rh, Kell, Kidd, Duffy, and MNS. A random 
subsample of 800 donor phenotypes was then evaluated for the 
probability of obtaining an exact match with respect to phenotype 
with a randomly selected patient from a particular ethnic 
group. Overall, there was a greater than 80 percent probability 
of finding an exact donor-recipient match for the K/k alleles in 
the Kell system. The probability ranged from 3 percent to 38 
percent, depending on the ethnicity and disparities in phenotypic 
profiles, for the Rh, Kidd, Duffy, and MNS systems. A significant 
donor-recipient phenotype mismatch ratio exists with certain 
blood group antigens such that, with current routine ABO and 
D matching practices, recipients of certain ethnic groups are 
predisposed to alloimmunization. Immunohematology 2011; 
27:12–19.
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As a premier destination medical center, the Mayo 
Clinic in Rochester, Minnesota, treats thousands of 
patients yearly. Demographic records in 2007 revealed that 
78 percent of patients were from the upper midwestern 
area of the United States, 20 percent were from other areas 
of the United States, and 2 percent were international 
patients.1 The majority of international patients were from 
the Persian Gulf States region (Saudi Arabia, Qatar, United 
Arab Emirates, and Kuwait) followed by patients from 
Canada, Europe, and South America.1
The 2008 population demographics of Olmsted County 
in southeastern Minnesota showed 86.6 percent Caucasian, 
3.0 percent Hispanic/Latino, 3.8 percent Black/African 
American, 5.1 percent Asian, and 1.4 percent other.2 As 
expected from this population demographic, blood donors 
at Mayo Clinic are predominantly Caucasian. In contrast, 
the Mayo Clinic patient demographics in the past decade 
show a steady increase in patients of various ethnic groups, 
including Somalis, Hispanics, Asians, and patients from 
Middle Eastern countries.
Because blood transfusion essentially constitutes a 
temporary transplant, there are risks of alloimmunization 
from exposure to foreign antigens on donor RBCs that can 
result in the formation of unexpected alloantibodies.3–6 
The development of RBC alloantibodies can lead to adverse 
complications including acute hemolytic transfusion 
reactions (AHTR), delayed hemolytic transfusion reactions 
(DHTR), and hemolytic disease of the fetus and newborn 
(HDFN), as well as laboratory findings such as delayed 
serologic transfusion reactions (DSTR) and a positive direct 
antiglobulin test (DAT).3,4,6,7 Other reports have proposed 
that allogeneic transfusion also predisposes patients to the 
formation of RBC autoantibodies, which may result in the 
development of autoimmune hemolytic anemia (AIHA), a 
condition that can lead to increased hemolysis of transfused 
RBCs.8,9
The purpose of our study was to determine the degree of 
patient and donor matching by comparing the phenotypic 
distribution of Mayo Clinic blood donors, based on 
molecular analysis, with the published Rh, Kell, Kidd, Duffy, 
and MNS phenotypes of various ethnic groups. Identifying, 
by means of DNA analysis, the predicted donor inventory 
profiles that closely match certain ethnic patients who may 
present with unexpected antibodies will help provide the 
best phenotype blood for these patients as well as triage 
any transfusion support with faster turnaround time in 
obtaining compatible blood. Although interethnic RBC 
phenotypic disparities are well documented, this research 
is the first comprehensive study comparing phenotypic 
differences between a predominantly Caucasian donor 
pool and an international, multiethnic10 group in a single 
report.
Materials and Methods
The results of molecular analysis of 1,000 blood donors 
were evaluated after approval from the Institutional Review 
Board. We limited molecular testing to group O and group 
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A donors to maximize inventory. Because D– donors were 
also selectively tested for inventory management purposes, 
the initial data showed a disproportionate 30 percent D–. To 
correct for the skewed D– sampling, a random subsample 
of 800 was selected from the initial 1,000 samples and 
stratified by D, such that the resulting distribution would 
simulate the known distribution of D phenotypes in the 
general Caucasian population of 85 percent D+ and 15 
percent D–. These 800 samples were then evaluated for the 
predicted phenotype distribution of Rh, Kell, Kidd, Duffy, 
and MNS.
Molecular testing was performed (BioArray BeadChip 
wHEA, Immucor, Norcross, GA). The BioArray wHEA 
predicted the RBC phenotype for 28 antigens in 11 blood 
group systems including Rh, Kell, Kidd, Duffy, MNS, 
Lutheran, Diego, Colton, Dombrock, Landsteiner-Wiener, 
and Scianna.
DNA was extracted using Genom-6, a robotic 
workstation that performs rapid isolation and purification 
of DNA without using solvent extraction and precipitation 
steps. The extraction was achieved by the tendency of DNA 
to bind or adsorb to a silica surface of magnetic beads in the 
presence of a chaotropic solution.
Statistical Methods
The antigen frequencies of Rh, Kell, Kidd, Duffy, and 
MNS from the 800 random subsamples were estimated 
with percentages. For the Kell, Kidd, and Duffy groups, 
overall exact chi-square goodness-of-fit tests (or their 
Monte Carlo estimates when necessary owing to sparse 
data) were used to compare the overall distributions with 
population estimates for each ethnic group. For the Rh and 
MNS groups, the percentage of each individual phenotype 
(i.e., the percent who were DCCee vs. all others) was 
compared with the corresponding published data of the 
various ethnic groups using exact chi-square goodness-of-
fit tests (or their Monte Carlo estimates when necessary). 
To adjust for the nine tests done per ethnicity within the Rh 
and MNS blood groups, the probability values from each of 
these individual tests were inflated by a factor of 9 (using 
an approximate Bonferroni methodology11). Further, we 
compared approximately 10 different ethnicities with our 
donor pool for each blood group. To adjust for this large 
number of comparisons, we considered probability values 
less than 0.01 to be statistically significant (overall type I 
error rate for a particular antigen group of 0.05/10 = 0.005; 
approximate Bonferroni methodology). All probability 
values were calculated using software (SAS version 9 
software, SAS Institute, Cary, NC). A statistical summary 
for the different blood groups is presented in Tables 1, 2, 
and 3, respectively.
As a separate analysis, we also calculated the 
probability of getting an exact match with respect to the 
phenotype from a randomly selected donor from our donor 
pool and a randomly selected patient from a particular 
ethnic group within each antigen group. These calculations 
assumed that the observed antigen distribution from the 
sample of 800 donors is representative of the population 
of our donors. See the Appendix for details on these 
calculations.











DCCee 21.4 16.0‡ 0.0§ 2.8§ 3.0§ 47.0§ 55.6§ 42.6§ 41.6§ 41.7§ 27.0† 20.7*
DCcEe 11.3 14.0* 0.7§ 0.7§ 4.0§ 30.0§ 26.7§ 12.1* 9.3* 34.7§ 26.0§ 14.8*
DccEE 2.9 3.0* 2.2* 0.3§ 1.0§ 6.0† 3.6* 2.6* 1.3† 7.1§ 7.0‡ 4.4*
Dccee 2.1 1.5* 81.9§ 64.1§ 42.0§ 0.3§ 0.6§ 1.9* 1.6* 1.7* 2.0* 10.8§
DCcee 35.0 32.0* 2.9§ 15.0§ 26.0§ 8.7§ 8.7§ 35.1* 32.9* 8.4§ 18.0§ 28.1‡
DccEe 12.4 13.0* 8.0‡ 2.5§ 16.0* 5.4§ 1.5§ 5.7§ 5.3§ 3.4§ 8.0‡ 10.3*
dccee 13.8 15.0* 2.9§ 1.4§ 7.0§ 1.0§ 0.0§ 0.0§ 6.0§ 0.2§ 3.0§ 10.3*
dCcee 0.5 0.4* 0.0§ 0.1* 1.0* 0.2* 0.0§ 0.0§ 0.8* 0.2* 0.2* 0.5*
dccEe 0.8 0.2* 0.0§ 0.2* 0.0§ 0.0§ 0.0§ 0.0§ 0.0§ 0.2* 0.2* 0.0§
Probability of finding 
same phenotype match 0.20 0.04 0.08 0.14 0.17 0.18 0.24 0.23 0.16 0.17 0.19
p-values are for comparison of the percentage of each phenotype in each ethnic group with the Mayo donor percentage.
*p-value ≥ 0.01 (not significant).
†0.01 > p-value ≥ 0.001.
‡0.001 > p-value ≥ 0.0001.
§p-value < 0.0001.
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Results
Results of the predicted Rh phenotype distributions of 
our blood donors compared with published distributions for 
the groups represented among our patients are summarized 
in Table 1. The distribution of the Rh phenotypes in our 
donor pool is similar to the known distribution among 
Caucasians, with the exception of the DCCee phenotype 
(21.4% for Mayo Clinic vs. 16.0% for Caucasians; p < 0.001).
The most common Rh phenotype in East Africans, 
Somalis, and the general Black population is Dccee, with 
frequencies of 81.9 percent, 64.1 percent, and 42 percent, 
respectively.
For Chinese and Thai people, the most common Rh 
phenotypes are DCCee and DCcEe, each approximately 
twice as frequent as donors at Mayo Clinic and Caucasians 
in general. For Asians of Indian descent, DCCee is the 
most common (42.6%), which is twice that of our donor 
population and Caucasians in general. However, three Rh 
phenotypes from Asians of Indian descent (DCcee, DCcEe, 
Dccee) showed no significant differences as compared with 
our donor pool. The predicted Rh phenotype distribution 
of Saudi Arabians closely resembles that of Caucasians and 
our donors (with the exception of Dccee, DCcee, and dccEe).
The probabilities of finding the same phenotype match 
for donor-recipient from our blood donors for the Rh blood 
groups for the various ethnic groups are presented in Table 1. 
The results show the probability of a random donor-recipient 
match ranged from 4 percent to 24 percent, depending on 
the ethnicity and the disparities in phenotypic profiles. 
For example, the chance of finding an exact Rh phenotype 
match between a random Mayo Clinic donor and an East 
African from Kampala, Uganda, is 4 percent; 8 percent 
for a Somali recipient, 17 percent to 18 percent for Asians 
of Chinese or Thai descent, 20 percent for a Caucasian 
recipient, and 24 percent for Asians of Indian descent. 












K–k+ 90.4 91.0 96.0 99.0 98.0 99.0 100.0 80.0 98.0 97.8
K+k– 0.4 0.2 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0
K+k+ 9.2 8.8 4.0 1.0 2.0 1.0 0.0 19.0 2.0 0.2
p-value * § § § § § § § §
Probability of finding 
same phenotype 
match
0.83 0.87 0.90 0.89 0.9 0.9 0.74 0.89 0.88
Kidd
Jk(a+b–) 27.5 26.3 29.7 31.3 51.0 47.9 31.8 50.0 25.0 23.5
Jk(a–b+) 20.9 23.4 21.7 21.3 8.0 10.3 42.8 42.0 18.0 27.1
Jk(a+b+) 51.6 50.3 48.7 47.3 41.0 41.9 25.4 8.0 57.0 49.4
p-value * * * § § § § † §
Probability of finding 
same phenotype 
match
0.38 0.38 0.38 0.37 0.37 0.31 0.27 0.40 0.38
Duffy
Fy(a+b–) 20.9 17.0 40.9 38.7 9.0 7.5 78.9 25.0 40.6 81.4 0.0 90.8
Fy(a–b+) 34.5 34.0 15.9 21.2 22.0 7.1 1.4 29.0 15.0 1.1 8.5 0.3
Fy(a+b+) 44.5 49.0 42.9 40.1 1.0 0.7 19.7 11.0 42.7 17.3 0.0 8.9
Fy(a–b–) 0.1 0.0 0.4 0.0 68.0 84.8 0.0 35.0 1.6 0.2 91.5 0.0
p-value § § § § § § § § § § §
Probability of finding 
same phenotype 
match
0.37 0.33 0.33 0.10 0.04 0.26 0.20 0.33 0.25 0.03 0.04
p-value is for comparing each ethnic group with the Mayo donor distribution.
*p-value ≥ 0.01 (not significant).
†0.01 > p-value ≥ 0.001.
‡0.001 > p-value ≥ 0.0001.
§p-value < 0.0001.
IMMUNOHEMATOLOGY, Volume 27, Number 1, 2011 15
RBC phenotype matching and ethnicity
Although DCCee (42%) is the most common published Rh 
phenotype among Asians of Indian descent, many Asians 
of Indian descent (32.9% to 35.1%; Table 1) also express the 
DCcee phenotype, which is the predominant phenotype 
(35.0%) among our donors. On the other hand, Somalis 
and East Africans predominantly express Dccee (64.1% and 
81.9%, respectively). Therefore, greater disparities exist 
because of the high incidence of the Dce (R0) phenotype 
and its low incidence among our donor pool (Table 1). 
Consequently, the large mismatched ratio and large number 
of donor exposures predisposes these recipients to the risk 
of alloimmunization to clinically significant antigens such 
as E and C. This large donor exposure for the mismatched 
antigens could be significant especially in obstetric and 
transfusion-dependent recipients.
Table 2 summarizes the phenotype distributions of 
the Kell, Kidd, and Duffy blood group systems. In the Kell 
system, the K+k+ phenotype among our donors (9.2%) 
is higher compared with that among Asians of Indian 
descent (4.0% and 1.0%, respectively), Somalis (1.0%), 
and Thai (0.0%), but significantly lower when compared 
with that among Saudi Arabians (19.0%). Although these 
discrepancies are statistically significant from a clinical 
standpoint (p < 0.0001), the probability of finding the same 
donor-recipient phenotype for the K/k alleles in the Kell 
blood group system, based on the observed distribution, is 
74 percent to 90 percent (Table 2).
The distribution in the Kidd system is comparable 
between our donors and the published data for Caucasians 
and Asians of Indian descent. However, significant 
differences (p < 0.0001) exist when compared with Blacks, 
Somalis, Thai, Saudi Arabians, and Mexicans (p < 0.01). 
The Jk(a+b–) phenotype in Blacks (51.0%), Somalis (47.9%), 
and Saudi Arabians (50.0%) is higher than our donor 
pool (27.5%), whereas the frequency of Jk(a+b+) among 
our donors (51.6%) is higher when compared with Blacks 
(41.0%) and Somalis (41.9%), and 6 times higher than Saudi 
Arabians (8.0%). Based on our statistical calculation of the 
observed distribution, the probability of finding a donor-
recipient phenotypic match for the Kidd blood group system 
ranges from 27 percent to 40 percent (Table 2).
For the Duffy blood group system, the distribution of 
phenotypes among our donors was found to be significantly 
different (p < 0.0001) when compared with all other 
ethnic groups, including Caucasians. The frequency of the 
Fy(a+b–) and Fy(a+b+) phenotypes among our donors is 
notable, 20.9 percent and 44.5 percent, respectively, but did 
not achieve statistical significance when compared with the 
published distribution in the general Caucasian population 
(17.0% and 49.0%, respectively). The Fy(a–b–) phenotype 
among our donors is only 0.1 percent compared with East 
Africans (91.5%), Somalis (84.8%), and Saudi Arabians 
(35.0%). The high incidence of Fy(a–b–) in Saudi Arabians 
is likely related to the presence of a Black and African 
admixture in the population of the Arabian Gulf States. 
The Fy(a–b–) phenotype confers resistance to certain 
malaria parasites and occurs predominantly among Blacks 
because of a genetically driven selection process.3 From 
the aforementioned differences in phenotypic profiles 
among ethnic groups in our study, our calculation shows 
Table 3. Statistical summary for the MNS blood group system
Mayo Donors 
(Reference) Caucasian12 Chinese15 Thai16 Northern Indian10 Somali14 East African13 Mexican18 Black12 Asian18
MNSs 21.2 24.0* 1.9§ 7.2§ 10.7§ 16.9† 12.3§ 17.2* 13.0§ 6.0§
MNS 3.1 4.0* 0.5§ 0.0§ 4.6* 3.6* 5.8* 4.4* 2.0* 0.6§
MNs 23.5 22.0* 47.4§ 40.3§ 27.8* 30.1‡ 28.3* 18.1‡ 33.0§ 41.2§
MSs 15.0 14.0* 3.3§ 8.1§ 13.3* 11.8* 10.9† 23.3§ 7.0§ 5.9§
MS 6.8 6.0* 0.5§ 0.0§ 5.5* 5.2* 2.9§ 11.2‡ 2.0§ 0.6§
Ms 10.0 8.0* 23.9§ 36.0§ 22.6§ 9.4* 18.1§ 15.4‡ 16.0§ 25.9§
NSs 4.2 6.0* 1.4§ 0.9§ 3.5* 2.0‡ 4.3* 2.6* 5.0* 2.2†
NS 0.3 1.0* 0.0§ 0.2* 1.2* 0.5* 0.0§ 0.7* 2.0† 0.2*
Ns 15.9 15.0* 21.1† 7.2§ 9.3§ 20.1* 13.0* 7.2§ 19.0* 17.4*
Probability of finding 
same phenotype match 0.16 0.18 0.17 0.15 0.17 0.15 0.15 0.17 0.17
p-values are for comparison of the percentage of each phenotype in each ethnic group with the Mayo donor percentage.
*p-value ≥ 0.01 (not significant).
†0.01 > p-value ≥ 0.001.
‡0.001 > p-value ≥ 0.0001.
§p-value < 0.0001.
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the probability of a donor-recipient phenotype match for 
the Duffy blood group system is 3 percent to 37 percent. 
Given the high incidence of the Fy(a–b–) phenotype 
among Somalis, East Africans, and Saudi Arabians, 
patients from these ethnic groups can be predisposed to 
alloimmunization to Duffy antigens owing to the relatively 
high incidence of Fy(a+b+) phenotype among our donor 
pool. Likewise, finding phenotypically matched blood 
for recipients of Asian descent, such as Chinese and Thai 
who are predominantly Fy(a+b–) (90.8% and 78.9% 
respectively), could be a difficult challenge. On the basis 
of the phenotypic distribution of our donor pool, some 
recipients can be predisposed to alloimmunization to Fyb.
The distributions for the MNS blood group system 
are summarized in Table 3. The most common MNS 
phenotypes in our donors are comparable with those of 
the general Caucasian population—MNs (23.5%), MNSs 
(21.2%), Ns (15.9%), and MSs (15.0%). However, significant 
differences exist when our donors are compared with the 
rest of the ethnic groups (probability values range from < 
0.01 to < 0.0001; Table 3). For Asians (Chinese, Thai, and 
Asians of Indian descent), the most common phenotypes 
are MNs and Ms. Ns in Chinese (21.1%) is notably higher 
in comparison to Thai (7.2%) and Asians of Indian descent 
(9.3%). The MNs phenotype is most common in both 
Somalis and East Africans, with Ns being the second most 
common phenotype in Somalis (20.1%) and Ms being the 
second most common phenotype in East Africans (18.1%). 
Mexicans show a different distribution pattern, with 
the most common phenotypes being MSs (23.3%), MNs 
(18.1%), and MNSs (17.2%). On the basis of these observed 
phenotypic distributions, the probability of finding a donor-
recipient phenotypic match is 15 percent to 18 percent for 
the MNS blood group system.
Discussion
RBC transfusion is a critical component of patient 
care, providing many benefits to those patients in need of 
oxygen-carrying capacity, but it also has inherent hazards. 
Transfusion recipients are at risk of alloimmunization owing 
to a disparity between donor and recipient antigen profiles. 
The risk associated with alloimmunization of recipients is 
attributable to individual and ethnic differences. These risks 
can be influenced by other factors, including dose, mode 
of exposure, and immunogenicity of the antigen.3,7,9,22,23 
The frequency of RBC-induced alloimmunization has 
been estimated to be between 2.6 percent and 60 percent, 
depending on the patient population studied and the 
method of study.4–7,23 The routine practice for selection of 
RBCs for blood transfusion has largely been restricted to 
matching for ABO and D despite lack of homogeneity of 
blood groups among individuals and across different ethnic 
groups. Exceptions include “transfusion responders” and 
the chronically transfused patients who are transfusion 
dependent and whose management sometimes dictates 
extended matching for other antigens because of preformed 
alloantibodies.4–9,22–24 Moreover, some patient populations, 
such as sickle cell patients, receive extended antigen 
matching in advance. The effects of alloimmunization 
include difficulty with future management and provision 
of transfusion support for these recipients. The situation 
is further exacerbated when patients present with multiple 
antibodies requiring extensive serologic workup that could 
delay patient care.3–9,22–25
Although some have strongly advocated for a more 
proactive approach in antigen matching for transfusion, 
others have suggested a more balanced approach, given 
the logistical complexities of resource and inventory 
management.5–7,22 In general, many transfusion 
experts support extended antigen matching for the 
chronically transfused patient because the frequency 
of alloimmunization in these patients can be as high as 
60 percent. However, expert opinion varies widely with 
regard to prophylactic extended antigen matching in 
nonchronically transfused patients to mitigate or avoid 
alloimmunization, as not all patients have an inherent risk 
of RBC sensitization. Higgins and Sloan4 reported evidence 
of a distinct “responder” phenotype and estimated that only 
13 percent of the general patient population were responders. 
In addition, they reported that the risk of immunologic 
response attributable to alloimmunization among these 
patients was only 30 percent and identified only 4 percent 
of new alloantibodies overall, suggesting that 70 percent of 
the responder phenotype do not usually make antibodies. 
Based on these results, the authors proposed a stochastic 
or nonanamnestic model of RBC alloimmunization.4 Their 
hypothesis implies that additional alloantibody formation 
is a rather random process that is not influenced by the 
number of preexisting patient antibodies.
However, in a 20-year multicenter retrospective 
study, Schonewille et al.5 reported 21.4 percent (140 of 
653) of nonhematologic alloimmunized patients in their 
cohort study formed additional antibodies resulting in 157 
new antibody specificities. In their findings, the authors 
reported 33.8 percent (221 of 653) of patients demonstrated 
multiple antibodies, whereas 57 percent (80 of 140) of those 
found with additional antibodies made the antibodies after 
receiving just one subsequent transfusion, averaging two 
units per transfusion episode. The authors further noted 
that extended phenotype matching for C, E, c, K, Fya, and 
Jka could have prevented 83 percent of the antibodies in 
J.R. Stubbs et al.
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316 patients. Given their data, the authors recommended 
extended antigen matching for nonhematologic patients to 
avoid extensive RBC alloimmunization.
In a similar study, Schonewille et al.6 also reported 
high antibody responders in previously alloimmunized 
hemoncology patients. Their study found that 21.7 percent 
(25 of 115) of previously alloimmunized hemoncology 
patients made additional antibodies after subsequent 
transfusions despite their diagnosis or compromised 
immune system from treatment. In essence, the findings of 
these two studies revealed a comparable increased ability 
to form additional antibodies in these two populations.
Our study explored the probability of obtaining an exact 
match with respect to phenotype from a randomly selected 
donor from our institution and a randomly selected patient 
from a particular ethnic group. As far as we know, our study 
is the first of its kind attempting to examine the probability 
of an exact donor-recipient match on the basis of phenotypic 
profiles. The probability of obtaining an exact phenotypic 
match from our donor pool and a random patient from 
various ethnic groups was calculated for Rh, Kell, Kidd, 
Duffy, and MNS blood group systems. These calculations 
assumed that the observed antigen distribution from the 
sample of 800 donors was representative of our donor 
population.
For example, the phenotype distribution of donors at 
our institution for K–k+, K+k–, and K+k+ is 90.4 percent, 
0.38 percent, and 9.3 percent, respectively, whereas the 
published distribution in Caucasians is 91 percent, 0.2 
percent, and 8.8 percent, respectively. If a single random 
Mayo Clinic donor and a single random Caucasian recipient 
are selected, the probability of an exact match is 83 percent. 
With the exception of Saudi Arabians, there is a greater 
than 80 percent probability of finding an exact donor-
recipient match for the K/k antigens in the Kell system. 
However, because of the significant disparities alluded to 
earlier, a high risk of alloimmunization (owing to K) for 
a mismatch still exists for Asians, Africans/Blacks, and 
Hispanic groups. Patients from these ethnic groups who are 
alloimmunized could benefit from additional prophylactic 
matching for K− units.
For the Rh blood group system, the probability of a 
random donor-recipient match ranged from 4 percent to 
24 percent, depending on the ethnicity and the disparities 
in phenotypic profiles. Therefore, the low probability of 
finding the same phenotype match can predispose certain 
ethnic recipients, such as Somalis and East Africans, to 
increased risk of alloimmunization to E and C.
In the Kidd system, there was a 27 percent to 40 percent 
probability of a match across all nationalities. In the Duffy 
system, the probabilities of a match ranged from 3 percent 
for Africans to as high as 37 percent for Caucasians. Given 
the phenotypic disparities in the Duffy system, Chinese 
and Thai individuals may be at risk for alloimmunization 
to Fyb because these two groups predominantly express the 
Fy(a+b–) phenotype.
In the MNS system, the probability of a donor-recipient 
match ranged from 15 percent to 18 percent. For the most 
part, S represents the biggest risk for alloimmunization 
to ethnic recipients based on phenotypic discrepancies. 
Therefore, additional prophylactic matching for S− units 
should be considered for alloimmunized recipients.
In summary, dual donor-patient molecular analysis 
has the potential for developing comprehensive 
electronic genotypic profiling and matching to decrease 
alloimmunization caused by donor-recipient antigen 
disparity. Furthermore, the practice of electronic genotypic 
matching has the potential to eliminate the need for repeat 
pretransfusion testing and additional serologic testing 
for a majority of patients. This could result in significant 
financial benefits for patients, hospitals, and governments 
in the future. Genotypic matching will also ease or 
eliminate labor-intensive serologic platforms or methods, 
such as adsorptions or elutions, which subject patients 
to long delays for management. If the full genotype of a 
particular patient is known, the turnaround time for finding 
phenotypically matched donor units can be improved with 
a computer-assisted database management system that has 
the ability to query a well-characterized and comprehensive 
donor genotype profile.
In conclusion, our study showed a significant donor-
recipient phenotype mismatch for certain blood group 
antigens, such that some ethnic groups are predisposed to 
a higher risk of alloimmunization to clinically significant 
antigens such as C, c, E, K, Jkb, and Fya. A diversified 
donor pool that has been characterized genotypically to 
predict RBC antigen expression has the potential to enable 
transfusion medicine practitioners to provide individualized 
RBC products for recipients through extended genotypic 
matching.
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Appendix
Additional Details and an Example Calculation 
for Determining an Exact Match Using Statistical 
Methods
The probability of getting an exact match with respect 
to the phenotype from a randomly selected donor from 
our donor pool and a randomly selected patient from a 
particular ethnic group within each antigen group was 
calculated. These calculations assumed that the observed 
antigen distribution from the sample of 800 donors is 
representative of the population of our donors. Using the Kell 
group as an example, the distribution of phenotypes in our 
donor pool is as follows: K–k+ 90.375 percent, K+k– 0.375 
percent, and K+k+ 9.25 percent. The published distribution 
of these  phenotypes in the general Caucasian population is 
as follows: 91 percent, 0.2 percent, and 8.8 percent. Thus, 
if a single Mayo Clinic blood donor and a single Caucasian 
recipient are randomly selected, the probability of an exact 
match is equal to the chance that the following scenario 
occurs: (the randomly selected Mayo Clinic donor is K–k+ 
AND the randomly selected Caucasian patient is K–k+) OR 
(the randomly selected Mayo Clinic donor is K+k– AND 
the randomly selected Caucasian patient is K+k–) OR (the 
randomly selected Mayo Clinic donor is K+k+ AND the 
randomly selected Caucasian patient is K+k+), resulting in 
the following calculation:
= P(K–k+|Mayo) × P(K–k+|Caucasian)
 + P(K+k–|Mayo) × P(K+k–|Caucasian)
 + P(K+k+|Mayo) × P(K+k+|Caucasian)
= (0.90375 × 0.91) + (0.00375 × 0.002)  
 + (0.0925 × 0.088)
= 0.83
In general terms, this calculation uses the following 
probability rules: (1) if events A and B are independent, 
then the P(A and B) = P(A) × P(B); and (2) if events A and B 
are mutually exclusive, then P(A or B) = P(A) + P(B).
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